Newton 21 Europe a company listed on the Free Market of Euronext, Brussels, finished the year 2008 following the market previsions.
The price of the shares showed since 01/01/2009 a progression of 55 %. Anticipating the net progress of the 2008 results in comparison with 2007:
- Turnover (100%): 33,5 million in 2008 compared to 33,3 million in 2007
- Gross Margin (100%): 20 million in 2008 compared to 8,3 million in 2007
- EBITDA (100% without holdings): 1,7 million in 2008 compared to 1,5 million in 2007
- Consolidated group’s net profit: 1,8 million versus -4,5 million 2007
- Equity capital: 11,68 million in 2008 versus 3,38 million in 2007
These results were achieved due to the group’s strong implementation in the healthcare communication that was expected since 2006 and as the effect of the undertaken restructuring measures targeting the graduate way out from the industry of traditional advertising. More than ever the group invests in the development of healthcare and well-being communication and in the enhancement of digital communication. The examples of this winning expansion strategy in Europe are creation of the new business entities specialised in healthcare communication in Switzerland and in Spain; and reinforcement of the digital communication company in Germany by absorption of a small and dynamic agency with the complementary activities. The group set up in November 2008 a new structure “Vivactis International”. The goal of this entity is to win European and worldwide budgets in healthcare communication and marketing against the biggest market players.
Note: VIVACTIS – NEWTON 21:
- is present in 12 European countries
- is acting under two brands: “Vivactis” and “Newton 21”
- focuses activities in: Brand activation, Healthcare and Well-Being communication , Digital communication
more info: www.newton21.eu
Contacts for additional information: Alain Mahaux, CEO : +32.(0)2.743.27.43 Rudy Roosemont, CFO: +32.(0)2.743.27.68 Jean-Claude Sauli : +33.(0)1.46.67.62.01
